ResMed Inc. RMD
| Analyste |
Entreprise |
Prix lors de l'analyse |
Prix cible |
Gain potentiel |
Date de publication |
| David Bailey |
Morgan Stanley |
248.14 $ |
286 $ |
37.86 % |
20/05/2025 |
| Brett Fishbin |
KeyBanc |
232.65 $ |
274 $ |
41.35 % |
24/04/2025 |
| Anthony Petrone |
Mizuho Securities |
211.49 $ |
265 $ |
53.51 % |
16/04/2025 |
| Adam Maeder |
Piper Sandler |
236.18 $ |
260 $ |
23.82 % |
31/01/2025 |
| Jonathan Block |
Stifel Nicolaus |
242.51 $ |
250 $ |
7.49 % |
12/12/2024 |
| Craig Wong-Pan |
RBC Capital |
238.95 $ |
224 $ |
-14.95 % |
01/10/2024 |
| Joe Vruwink |
Robert W. Baird |
246.18 $ |
280 $ |
33.82 % |
23/09/2024 |
| Mike Polark |
Wolfe Research |
250.88 $ |
180 $ |
-70.88 % |
18/09/2024 |
| Craig Wong-Pan |
RBC Capital |
194.27 $ |
187 $ |
-7.27 % |
10/04/2024 |
| Mike Matson |
Stifel Nicolaus |
198.03 $ |
224 $ |
25.97 % |
01/04/2024 |
| Suraj Kalia |
Oppenheimer |
134.65 $ |
175 $ |
40.35 % |
27/10/2023 |
| Mike Matson |
Needham |
153.89 $ |
180 $ |
26.11 % |
06/09/2023 |
| Craig Wong-Pan |
RBC Capital |
197.57 $ |
244 $ |
46.43 % |
20/06/2022 |
| Suraj Kalia |
Oppenheimer |
253.77 $ |
312 $ |
58.23 % |
14/10/2021 |
| Sean Laaman |
Morgan Stanley |
271.87 $ |
250 $ |
-21.87 % |
04/08/2021 |
| Anthony Petrone |
Jefferies |
264.75 $ |
240 $ |
-24.75 % |
28/07/2021 |